Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-391 vs Atorvastatin/Ezetimibe in Healthy Males
NCT02501200Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Aug 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of CKD-391 in hypercholesterolemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Started Aug 2015; status: completed.
02
Drugs
CKD-391
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02501200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02501200.